CAR T-Cell Therapy MB-102 Granted FDA Orphan Drug Designation for AML

July 24, 2019 – The CAR T-Cell therapy MB-102 has been granted an Orphan Drug Designation by the FDA, according to Mustang Bio, Inc, the manufacturer of the investigational treatment. MB-102, which targets CD123, previously received Orphan Drug status for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The designation incentivizes the development of novel therapies for rare diseases (<200,000 US cases) or diseases for ... (leggi tutto)